This article previews a clinical trial report on an evening THC formulation tested for reducing trauma-related nightmares in people with PTSD. Readers will find a patient-focused trial overview describing methods, tolerability, and implications for sleep-targeted PTSD care.
Key Takeaways
- Randomized trial enrolled over 170 PTSD patients and lasted ten weeks
- Dronabinol reduced nightmare severity by 3.7 points versus 2.2 for placebo on an 8-point scale
- Over one third of treated patients achieved complete nightmare remission by week ten